首页 > 最新文献

Neurogastroenterology & Motility最新文献

英文 中文
Natural history of symptoms and prognostic information of the rapid drink challenge and solid bolus swallows in esophagogastric junction outflow obstruction defined by manometry 通过测压法确定食管胃交界处流出道梗阻的症状自然史和快速饮水挑战与固体栓吞咽的预后信息
Pub Date : 2023-12-10 DOI: 10.1111/nmo.14720
Axel Josefsson, Magnus Simrén, Adam Smolak, Nour Sabbagh, Hans Törnblom
Esophagogastric junction outflow obstruction (EGJOO) is a condition characterized by poor relaxation of the lower esophageal sphincter (LES), which can manifest as dysphagia and chest pain. The best treatment of EGJOO is unknown as some patients improve without any specific therapy, whereas some patients undergo invasive therapy. Currently, prognostic factors are lacking. We aimed to assess the long-term prognosis and predictors of dysphagia and chest pain by the rapid drink challenge and solid bolus swallows in EGJOO.
食管胃交界处流出道梗阻(EGJOO)是一种以食管下括约肌(LES)松弛不良为特征的疾病,可表现为吞咽困难和胸痛。食管下段括约肌阻塞的最佳治疗方法尚不清楚,因为有些患者无需任何特殊治疗即可好转,而有些患者则需要接受侵入性治疗。目前还缺乏预后因素。我们的目的是通过对 EGJOO 患者进行快速饮水挑战和固体栓剂吞咽来评估其长期预后以及吞咽困难和胸痛的预测因素。
{"title":"Natural history of symptoms and prognostic information of the rapid drink challenge and solid bolus swallows in esophagogastric junction outflow obstruction defined by manometry","authors":"Axel Josefsson, Magnus Simrén, Adam Smolak, Nour Sabbagh, Hans Törnblom","doi":"10.1111/nmo.14720","DOIUrl":"https://doi.org/10.1111/nmo.14720","url":null,"abstract":"Esophagogastric junction outflow obstruction (EGJOO) is a condition characterized by poor relaxation of the lower esophageal sphincter (LES), which can manifest as dysphagia and chest pain. The best treatment of EGJOO is unknown as some patients improve without any specific therapy, whereas some patients undergo invasive therapy. Currently, prognostic factors are lacking. We aimed to assess the long-term prognosis and predictors of dysphagia and chest pain by the rapid drink challenge and solid bolus swallows in EGJOO.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138575450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions 大多数患有肠脑相互作用疾病的患者接受药物治疗时,都会发生严重或中度的药物基因相互作用
Pub Date : 2023-12-10 DOI: 10.1111/nmo.14722
Revati Varma, Jeffrey P. Staab, Eric T. Matey, Jessica A. Wright, Brototo Deb, Konstantinos N. Lazaridis, Lawrence A. Szarka, Kent R. Bailey, Adil E. Bharucha
How variations predicted by pharmacogenomic testing to alter drug metabolism and therapeutic response affect outcomes for patients with disorders of gut- brain interaction is unclear.
目前还不清楚药物基因组学检测所预测的改变药物代谢和治疗反应的变异如何影响肠道-大脑相互作用紊乱患者的治疗效果。
{"title":"Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions","authors":"Revati Varma, Jeffrey P. Staab, Eric T. Matey, Jessica A. Wright, Brototo Deb, Konstantinos N. Lazaridis, Lawrence A. Szarka, Kent R. Bailey, Adil E. Bharucha","doi":"10.1111/nmo.14722","DOIUrl":"https://doi.org/10.1111/nmo.14722","url":null,"abstract":"How variations predicted by pharmacogenomic testing to alter drug metabolism and therapeutic response affect outcomes for patients with disorders of gut- brain interaction is unclear.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"173 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138575158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Translation of an existing implantable cardiac monitoring device for measurement of gastric electrical slow-wave activity 改造现有的植入式心脏监测设备,测量胃电慢波活动
Pub Date : 2023-12-07 DOI: 10.1111/nmo.14723
Jarrah M. Dowrick, Lisa Jungbauer Nikolas, Sarah J. Offutt, Peter Tremain, Jonathan C. Erickson, Timothy R. Angeli-Gordon
Despite evidence that slow-wave dysrhythmia in the stomach is associated with clinical conditions such as gastroparesis and functional dyspepsia, there is still no widely available device for long-term monitoring of gastric electrical signals. Actionable biomarkers of gastrointestinal health are critically needed, and an implantable slow-wave monitoring device could aid in the establishment of causal relationships between symptoms and gastric electrophysiology. Recent developments in the area of wireless implantable gastric monitors demonstrate potential, but additional work and validation are required before this potential can be realized.
尽管有证据表明胃部慢波节律失常与胃痉挛和功能性消化不良等临床症状有关,但目前仍没有可长期监测胃电信号的广泛装置。胃肠道健康急需可操作的生物标志物,而植入式慢波监测设备可帮助确定症状与胃电生理学之间的因果关系。无线植入式胃监护仪领域的最新发展显示了其潜力,但在实现这一潜力之前还需要更多的工作和验证。
{"title":"Translation of an existing implantable cardiac monitoring device for measurement of gastric electrical slow-wave activity","authors":"Jarrah M. Dowrick, Lisa Jungbauer Nikolas, Sarah J. Offutt, Peter Tremain, Jonathan C. Erickson, Timothy R. Angeli-Gordon","doi":"10.1111/nmo.14723","DOIUrl":"https://doi.org/10.1111/nmo.14723","url":null,"abstract":"Despite evidence that slow-wave dysrhythmia in the stomach is associated with clinical conditions such as gastroparesis and functional dyspepsia, there is still no widely available device for long-term monitoring of gastric electrical signals. Actionable biomarkers of gastrointestinal health are critically needed, and an implantable slow-wave monitoring device could aid in the establishment of causal relationships between symptoms and gastric electrophysiology. Recent developments in the area of wireless implantable gastric monitors demonstrate potential, but additional work and validation are required before this potential can be realized.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138553995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationships among symptoms of gastroparesis to those of avoidant/restrictive food intake disorder in patients with gastroparesis 胃痉挛患者的胃痉挛症状与回避性/限制性食物摄入障碍症状之间的关系
Pub Date : 2023-12-07 DOI: 10.1111/nmo.14725
Erin Hollis, Helen Burton Murray, Henry P. Parkman
Patients with symptoms of gastroparesis (Gp) often reduce food intake in attempt to manage their symptoms. Up to 40% of adults with Gp have been reported to have symptoms of a non-body image-based eating disorder, avoidant/restrictive food intake disorder (ARFID). However, whether ARFID symptoms precede or follow the diagnosis of Gp is unknown.
有胃痉挛(Gp)症状的患者通常会减少食物摄入量,试图控制症状。据报道,多达 40% 的成人胃瘫患者有非身体形象性进食障碍的症状,即回避/限制性食物摄入障碍(ARFID)。然而,ARFID 症状是在 Gp 诊断之前还是之后出现尚不清楚。
{"title":"Relationships among symptoms of gastroparesis to those of avoidant/restrictive food intake disorder in patients with gastroparesis","authors":"Erin Hollis, Helen Burton Murray, Henry P. Parkman","doi":"10.1111/nmo.14725","DOIUrl":"https://doi.org/10.1111/nmo.14725","url":null,"abstract":"Patients with symptoms of gastroparesis (Gp) often reduce food intake in attempt to manage their symptoms. Up to 40% of adults with Gp have been reported to have symptoms of a non-body image-based eating disorder, avoidant/restrictive food intake disorder (ARFID). However, whether ARFID symptoms precede or follow the diagnosis of Gp is unknown.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138554067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The secreted protein P75 of Lactobacillus rhamnosus GG regulates the SERT expression via EGFR and NF‐κB pathway 鼠李糖乳杆菌GG分泌蛋白P75通过EGFR和NF‐κB途径调控SERT的表达
Pub Date : 2022-08-16 DOI: 10.1111/nmo.14437
Xin Wang, Ying Li, Jun-Jie Hou, Zelan Wang, Yiming Chen, Shuai Su, Xin Xu, J Zhang, Weilong Zhong, Bangmao Wang, Yuming Wang
To investigate the mechanism of Lactobacillus rhamnosus GG (LGG)‐secreted protein, P75, on the regulation of the expression of serotonin transporter (SERT) through the epidermal growth factor receptor (EGFR) and nuclear factor‐κB (NF‐κB) pathway.
目的探讨鼠李糖乳杆菌GG (LGG)分泌蛋白P75通过表皮生长因子受体(EGFR)和核因子κB (NF - κB)通路调控血清素转运体(SERT)表达的机制。
{"title":"The secreted protein P75 of Lactobacillus rhamnosus GG regulates the SERT expression via EGFR and NF‐κB pathway","authors":"Xin Wang, Ying Li, Jun-Jie Hou, Zelan Wang, Yiming Chen, Shuai Su, Xin Xu, J Zhang, Weilong Zhong, Bangmao Wang, Yuming Wang","doi":"10.1111/nmo.14437","DOIUrl":"https://doi.org/10.1111/nmo.14437","url":null,"abstract":"To investigate the mechanism of Lactobacillus rhamnosus GG (LGG)‐secreted protein, P75, on the regulation of the expression of serotonin transporter (SERT) through the epidermal growth factor receptor (EGFR) and nuclear factor‐κB (NF‐κB) pathway.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85270828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overlaps with bladder pain syndrome and irritable bowel syndrome are associated with higher symptom burden and reduced quality of life in functional dyspepsia 与膀胱疼痛综合征和肠易激综合征重叠与功能性消化不良患者更高的症状负担和生活质量降低相关
Pub Date : 2022-05-24 DOI: 10.1111/nmo.14414
F. Wuestenberghs, M. Baron, C. Melchior, C. Desprez, J. Cornu, A. Leroi, G. Gourcerol
Functional dyspepsia and bladder pain syndrome are well‐known to overlap with irritable bowel syndrome. Whether functional dyspepsia overlaps with bladder pain syndrome remains unknown. Our aim was to evaluate the presence of bladder pain syndrome in functional dyspepsia patients and its impact.
众所周知,功能性消化不良和膀胱疼痛综合征与肠易激综合征有重叠。功能性消化不良是否与膀胱疼痛综合征重叠尚不清楚。我们的目的是评估功能性消化不良患者膀胱疼痛综合征的存在及其影响。
{"title":"Overlaps with bladder pain syndrome and irritable bowel syndrome are associated with higher symptom burden and reduced quality of life in functional dyspepsia","authors":"F. Wuestenberghs, M. Baron, C. Melchior, C. Desprez, J. Cornu, A. Leroi, G. Gourcerol","doi":"10.1111/nmo.14414","DOIUrl":"https://doi.org/10.1111/nmo.14414","url":null,"abstract":"Functional dyspepsia and bladder pain syndrome are well‐known to overlap with irritable bowel syndrome. Whether functional dyspepsia overlaps with bladder pain syndrome remains unknown. Our aim was to evaluate the presence of bladder pain syndrome in functional dyspepsia patients and its impact.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81178506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Gastroenterology Trainees’ Attitudes and Knowledge towards Patients with Disorders of Gut‐Brain Interaction 胃肠病学学员对肠脑相互作用紊乱患者的态度和认识
Pub Date : 2022-05-24 DOI: 10.1111/nmo.14410
Yuying Luo, R. Dixon, B. Shah, L. Keefer
Disorders of gut‐brain interaction (DGBI) are highly prevalent, estimated to affect about 40% of the global population. Patients with DGBI are still inadequately treated and face stigma which adversely impacts their disease course.
肠脑相互作用紊乱(DGBI)非常普遍,估计影响全球约40%的人口。DGBI患者仍未得到充分治疗,并面临耻辱,这对其病程产生不利影响。
{"title":"Gastroenterology Trainees’ Attitudes and Knowledge towards Patients with Disorders of Gut‐Brain Interaction","authors":"Yuying Luo, R. Dixon, B. Shah, L. Keefer","doi":"10.1111/nmo.14410","DOIUrl":"https://doi.org/10.1111/nmo.14410","url":null,"abstract":"Disorders of gut‐brain interaction (DGBI) are highly prevalent, estimated to affect about 40% of the global population. Patients with DGBI are still inadequately treated and face stigma which adversely impacts their disease course.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89723153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis 对系统性硬化症患者食管运动障碍的更精确分类
Pub Date : 2022-05-20 DOI: 10.1111/nmo.14416
E. Marabotto, V. Savarino, E. Savarino
Systemic sclerosis (SSc) is a chronic and generalized disease affecting the connective tissue of the skin and many internal organs, in particular the gastrointestinal tract. The esophagus is involved in up to 80% of the cases and represents a major cause of serious morbidities that deeply impact on the quality of life and survival of patients. Indeed, the presence of esophageal dysfunction is a good prognostic indicator in SSc, primarily due to its impact on pulmonary disease. Thus, the detection of esophageal motility alterations plays a critical role to prevent the development of both esophageal and pulmonary complications and to improve the survival of these patients. Currently, this diagnostic work‐up has been limited to the use of esophageal manometry, which is considered the gold standard for the evaluation of motor physiology and pathophysiology of this organ in different clinical situations. However, in recent years, new equipments such as high‐resolution (−impedance) manometry and functional luminal imaging probe have been developed and used in many esophageal clinical settings, including SSc. In this mini‐review, we summarize current evidence regarding esophageal dysmotility, in the light of new data on secondary peristalsis published in this issue of the journal.
系统性硬化症(SSc)是一种慢性和全身性疾病,影响皮肤结缔组织和许多内脏器官,特别是胃肠道。高达80%的病例涉及食道,是严重发病的主要原因,严重影响患者的生活质量和生存。事实上,食管功能障碍的存在是SSc的一个很好的预后指标,主要是由于其对肺部疾病的影响。因此,检测食管运动改变对预防食管和肺并发症的发生以及提高患者的生存率具有重要作用。目前,这项诊断工作仅限于使用食管测压法,这被认为是在不同临床情况下评估该器官运动生理和病理生理的金标准。然而,近年来,诸如高分辨率(−阻抗)测压仪和功能性腔内成像探头等新设备已被开发并用于许多食管临床环境,包括SSc。在这篇小型综述中,我们根据发表在本期杂志上的关于继发性蠕动的新数据,总结了目前关于食管运动障碍的证据。
{"title":"Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis","authors":"E. Marabotto, V. Savarino, E. Savarino","doi":"10.1111/nmo.14416","DOIUrl":"https://doi.org/10.1111/nmo.14416","url":null,"abstract":"Systemic sclerosis (SSc) is a chronic and generalized disease affecting the connective tissue of the skin and many internal organs, in particular the gastrointestinal tract. The esophagus is involved in up to 80% of the cases and represents a major cause of serious morbidities that deeply impact on the quality of life and survival of patients. Indeed, the presence of esophageal dysfunction is a good prognostic indicator in SSc, primarily due to its impact on pulmonary disease. Thus, the detection of esophageal motility alterations plays a critical role to prevent the development of both esophageal and pulmonary complications and to improve the survival of these patients. Currently, this diagnostic work‐up has been limited to the use of esophageal manometry, which is considered the gold standard for the evaluation of motor physiology and pathophysiology of this organ in different clinical situations. However, in recent years, new equipments such as high‐resolution (−impedance) manometry and functional luminal imaging probe have been developed and used in many esophageal clinical settings, including SSc. In this mini‐review, we summarize current evidence regarding esophageal dysmotility, in the light of new data on secondary peristalsis published in this issue of the journal.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"193 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75874539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Three dimension high‐definition manometry in evaluation of anorectal function in 104 normal infants and children: A clinical study from China 三维高清晰度测压法评价104例正常婴幼儿肛肠功能的临床研究
Pub Date : 2022-05-16 DOI: 10.1111/nmo.14395
Jiawei Zhao, Yanan Zhang, Yuning Xiong, Jingbin Du, Yong-wei Chen, Wei-hong Guo, Jinshi Huang
We aimed to evaluate anorectal function of normal infants and children through three dimension high‐definition anorectal manometry (3D ARM) to fill the research blank in this area.
我们旨在通过三维高清晰度肛肠测压仪(3D ARM)来评估正常婴幼儿的肛肠功能,以填补这一领域的研究空白。
{"title":"Three dimension high‐definition manometry in evaluation of anorectal function in 104 normal infants and children: A clinical study from China","authors":"Jiawei Zhao, Yanan Zhang, Yuning Xiong, Jingbin Du, Yong-wei Chen, Wei-hong Guo, Jinshi Huang","doi":"10.1111/nmo.14395","DOIUrl":"https://doi.org/10.1111/nmo.14395","url":null,"abstract":"We aimed to evaluate anorectal function of normal infants and children through three dimension high‐definition anorectal manometry (3D ARM) to fill the research blank in this area.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"273 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91511380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Letter in response to Black et al. (2020): Authors’ Reply 对Black et al.(2020)的回复:作者回复
Pub Date : 2022-04-25 DOI: 10.1111/nmo.14388
C. Black, A. Ford
To the editor; We are grateful to Trindade et al. 1 for their interest in our paper, which examined the factor structure of the visceral sensitivity index (VSI) among 811 individuals with Rome IV irritable bowel syndrome (IBS) from the UK.2 The VSI is a measure of gastrointestinal symptomspecific anxiety that had not been validated in the UK population. The original validation study from the USA reported an unifactorial structure,3 whereas our analysis identified three separate factors. Moreover, we found no evidence that VSI mediated the relationship between measures of generalized anxiety and symptom severity in IBS. In their analysis of 424 Swedish patients with IBS, Trindade et al. report a singlefactor structure in agreement with the original VSI study.1 They discuss that cultural and linguistic differences between studies may have influenced the responses to the VSI, but this seems unlikely. The original VSI was developed in English, and while differences in spelling and usage exist between the UK and the USA, there is nothing that should affect understanding of the VSI in the UK population. Whether Trindade et al. translated the VSI into Swedish is unclear. However, this is unlikely to explain the differences between their results and ours, given the similarity between their findings and those from the USA. The cultural concepts discussed in the VSI, such as eating out in restaurants, will be familiar to people from any Westernized society. Consequently, methodological differences between the studies are likely to be of greater relevance to understanding the contrasting results. The original validation study involved only 96 individuals who selfidentified with IBS, of whom 85% met Rome II criteria.3 We also recruited individuals who selfidentified with IBS, but our study cohort was much larger, and we only included those who met diagnostic criteria for IBS. Moreover, we defined IBS using the current Rome IV criteria.4 These are more specific for diagnosing IBS compared with previous iterations,5,6 but they also select for patients who have more severe symptoms and greater psychological comorbidity.7,8 This may explain why analysis of the VSI in our study yielded a different factor structure than was originally described. Trindade et al. recruited patients referred to a tertiary center among whom reporting gastrointestinal symptomspecific anxiety may conceivably be more homogeneous. Furthermore, it is unclear how they defined IBS in their study. Importantly, their results are not fully published, limiting comparison with our study; however, we agree that further work to validate and refine the VSI is warranted.
给编辑;我们感谢Trindade et al. 1对我们的论文感兴趣,该论文研究了来自英国的811例罗马IV型肠易激综合征(IBS)患者的内脏敏感性指数(VSI)的因子结构。VSI是胃肠道症状特异性焦虑的一种测量方法,尚未在英国人群中得到验证。来自美国的原始验证研究报告了一个单因素结构,而我们的分析确定了三个独立的因素。此外,我们没有发现VSI介导IBS中广泛性焦虑测量和症状严重程度之间的关系的证据。在他们对424名瑞典IBS患者的分析中,Trindade等人报告了与原始VSI研究一致的单因素结构他们讨论了研究之间的文化和语言差异可能影响了对VSI的反应,但这似乎不太可能。最初的VSI是在英语中开发的,虽然英国和美国之间存在拼写和用法的差异,但没有什么应该影响英国人口对VSI的理解。Trindade等人是否将VSI翻译成瑞典语尚不清楚。然而,考虑到他们的发现与美国的发现之间的相似性,这不大可能解释他们的结果与我们的结果之间的差异。在VSI中讨论的文化概念,比如在餐馆吃饭,对于来自任何西化社会的人来说都是熟悉的。因此,研究之间的方法差异可能对理解对比结果具有更大的相关性。最初的验证研究只涉及96名自认为患有肠易激综合征的个体,其中85%符合罗马II标准我们也招募了自认为患有肠易激综合征的人,但我们的研究队列要大得多,而且我们只包括那些符合肠易激综合征诊断标准的人。此外,我们使用当前的罗马IV标准定义肠易激综合征与之前的迭代相比,这些方法在诊断肠易激综合征方面更具体,但它们也会选择那些症状更严重、心理合并症更严重的患者。这也许可以解释为什么在我们的研究中对VSI的分析产生了不同于最初描述的因素结构。Trindade等人招募了转介到三级中心的患者,其中报告胃肠道症状特异性焦虑的患者可能更为均匀。此外,尚不清楚他们在研究中如何定义肠易激综合征。重要的是,他们的结果没有完全发表,限制了与我们研究的比较;然而,我们同意进一步验证和完善VSI的工作是有必要的。
{"title":"Letter in response to Black et al. (2020): Authors’ Reply","authors":"C. Black, A. Ford","doi":"10.1111/nmo.14388","DOIUrl":"https://doi.org/10.1111/nmo.14388","url":null,"abstract":"To the editor; We are grateful to Trindade et al. 1 for their interest in our paper, which examined the factor structure of the visceral sensitivity index (VSI) among 811 individuals with Rome IV irritable bowel syndrome (IBS) from the UK.2 The VSI is a measure of gastrointestinal symptomspecific anxiety that had not been validated in the UK population. The original validation study from the USA reported an unifactorial structure,3 whereas our analysis identified three separate factors. Moreover, we found no evidence that VSI mediated the relationship between measures of generalized anxiety and symptom severity in IBS. In their analysis of 424 Swedish patients with IBS, Trindade et al. report a singlefactor structure in agreement with the original VSI study.1 They discuss that cultural and linguistic differences between studies may have influenced the responses to the VSI, but this seems unlikely. The original VSI was developed in English, and while differences in spelling and usage exist between the UK and the USA, there is nothing that should affect understanding of the VSI in the UK population. Whether Trindade et al. translated the VSI into Swedish is unclear. However, this is unlikely to explain the differences between their results and ours, given the similarity between their findings and those from the USA. The cultural concepts discussed in the VSI, such as eating out in restaurants, will be familiar to people from any Westernized society. Consequently, methodological differences between the studies are likely to be of greater relevance to understanding the contrasting results. The original validation study involved only 96 individuals who selfidentified with IBS, of whom 85% met Rome II criteria.3 We also recruited individuals who selfidentified with IBS, but our study cohort was much larger, and we only included those who met diagnostic criteria for IBS. Moreover, we defined IBS using the current Rome IV criteria.4 These are more specific for diagnosing IBS compared with previous iterations,5,6 but they also select for patients who have more severe symptoms and greater psychological comorbidity.7,8 This may explain why analysis of the VSI in our study yielded a different factor structure than was originally described. Trindade et al. recruited patients referred to a tertiary center among whom reporting gastrointestinal symptomspecific anxiety may conceivably be more homogeneous. Furthermore, it is unclear how they defined IBS in their study. Importantly, their results are not fully published, limiting comparison with our study; however, we agree that further work to validate and refine the VSI is warranted.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85343174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurogastroenterology & Motility
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1